Editing Hemispherian

{{DISPLAYTITLE:Hemispherian}}
{{Infobox company
| name = Hemispherian AS
| org_number = 925333409
| founded = 2020-06-15
| employees = 5
| address = Norway
| industry = 72.100 – Biotechnology research
| website = https://hemispherian.com
| nht_category = Startup
| description = Hemispherian is an innovative clinical-stage pharmaceutical company developing a novel class of small molecule drugs targeting the TET2 enzyme as a targeted therapy for particularly aggressive cancers. TET2 is a DNA demethylase enzyme linked to cancer progression when mutated or dysregulated.
| notes = No disclosed revenue or funding. 5 employees. Clinical-stage means active drug development pipeline.
| related_companies = [[IC Targets]], [[Exact Therapeutics]], [[Seald]], [[Norway Health Tech]]
| categories = Norway Health Tech, Startups, Biotechnology, Oncology, Drug Development
| sources = https://hemispherian.com; https://data.brreg.no/enhetsregisteret/api/enheter/925333409
}}

== About ==

Hemispherian AS is a Norwegian clinical-stage pharmaceutical company developing novel small molecule drugs targeting the TET2 enzyme for the treatment of aggressive cancers.

== Technology ==

Hemispherian's drug development approach focuses on the TET2 (Ten-Eleven Translocation 2) enzyme — a DNA demethylase that plays a critical role in epigenetic regulation. Dysregulation or mutation of TET2 is implicated in the progression of various aggressive cancers. The company is developing a novel class of small molecules that target TET2 as a therapeutic strategy.

== Pipeline ==

Hemispherian is at the clinical-stage, indicating active development toward or within clinical trials. The company has published key publications related to its scientific approach.

== References ==
<references/>

[[Category:Norway Health Tech]]
[[Category:Startups]]
[[Category:Biotechnology]]
[[Category:Oncology]]
[[Category:Drug Development]]